Citations

Showing 10 of 108119 citations.

The Superficial Face Dissection as an Example for Integrating Clinical Approaches, Authentic Learning, and Changing Perspectives in Anatomy Dissection
Cotofana, Sebastian , Lachman, Nirusha , Cotofana, Sebastian

Mayo Clinic

Anatomical Sciences Education | April 3, 2019 | Volume: 13 | Issue: 1 | Pages: 117-121

10.1002/ase.1881 | PMID 30941866 Get It

Hands‐on dissection‐based learning of anatomy offers an unique and valued experience for medical students. Too often however, the inexperienced student's focus is to avoid damage to unfamiliar structures instead of understanding spatial relationships between structures. This results in unfortunate surrender of a critical learning experience. Additionally, approaches to dissection and anatomic exposure share little alignment to clinical approaches, making it less powerful in clinical applicability. The goal of this viewpoint commentary is based on the experience of the two authors and aims to demonstrate opportunity to introduce clinical approaches for dissection while incorporating relevant anatomical concepts in medical school curriculum that aligns with authentic healthcare practice. Using the dissections of the superficial face as a relevant and current topic of clinical interest, we point out that applying the currently performed dissection approach (medial‐to‐lateral) falls short of providing sufficient knowledge and understanding of the layered arrangement of facial structures. The lateral‐to‐medial approach, as performed in surgical face lifting procedures would offer a better understanding of the layers of the face and especially the superficial musculoaponeurotic system (SMAS) accounting for the difficulties of facial dissections on embalmed cadavers. This commentary could offer a potential change in paradigm for students and course facilitators for how to maximize the knowledge transfer during facial dissections. It potentially opens a door to rethink dissection‐based learning of anatomy toward techniques and approaches that are aligned to surgical access pathways and thus considered more clinically relevant.
Food Cravings and Eating: The Role of Experiential Avoidance
Fahrenkamp, Amy J., Darling, Katherine E. , Ruzicka, Elizabeth B. , Sato, Amy F.

Mayo Clinic

International Journal of Environmental Research and Public Health | April 3, 2019 | Volume: 16 | Issue: 7 | Pages: 1181

10.3390/ijerph16071181 | PMID 30986941 Get It

Food cravings have been associated with problematic eating behaviors, such as emotional eating. Late adolescence is an important developmental period to examine this association, as late adolescents have greater independence in food choices as well as potentially higher demands during a transitional period of their lives. Mechanisms underlying the association between food cravings and problematic eating remain unclear. This study examined whether experiential avoidance (EA) may be one possible mechanism mediating the association between higher levels of food cravings and problematic eating behaviors. Late adolescents (n = 174) completed measures assessing EA, food cravings, and three problematic eating behaviors: emotional eating, cognitive restraint, and uncontrolled eating. Height and weight were measured objectively to calculate body mass index (BMI). Food cravings were positively associated with emotional eating and mediated by EA. EA also significantly mediated the association between greater cognitive restraint and greater food cravings. No significant mediation was detected for food cravings and uncontrolled eating. Future research may consider EA as a treatment target in intervention strategies for late adolescents seeking to decrease emotional or restrained eating behaviors.
Postoperative Pain and 14-Day Recovery in Children Undergoing Adenotonsillectomy: Low Thermal Damage Device Versus Electrosurgery
Blake, Kathryn , Hossain, Jobayer , Chafin, Brett, Black, Angela P., Schrum, Stefanie, Josephson, Gary D. , Blake, Kathryn V

Mayo Clinic

Ear, Nose & Throat Journal | April 3, 2019 | Volume: 98 | Issue: 4 | Pages: E1-E7

10.1177/0145561319838941 | PMID 30939911 Get It

This was a randomized controlled trial of low thermal damage device versus traditional electrosurgery in children 3 to 17 years old with a clinical diagnosis of sleep disordered breathing, obstructive sleep apnea with adenotonsillar hypertrophy, or recurrent adenotonsillitis. Pain score (Wong-Baker FACES pain scale) was recorded each morning before eating, drinking, or administering pain medication for 14 days postoperatively. Seventy-five children were enrolled. There was no difference in the rate of decrease in pain scores. A significant interaction between rate of pain decrease and number of pain medication doses was present ( P < .0001). Median number of pain medication doses was greater with electrosurgery (36, range: 7-49) versus low thermal device (21, range: 2-124; P = .001). Pain scores reached 0 after a median of 7 days (95% confidence interval [CI], 5.2-8.6) for low thermal device and 9 days (95% CI, 8.0-10.0) for electrosurgery ( P = .67). One child randomized to electrosurgery was withdrawn due to hospitalization for postoperative bleed. In children, low thermal device results in significantly less pain medication used during the postoperative period than electrosurgery.
Clots retrieved by mechanical thrombectomy from acute ischemic stroke patients show no evidence of bacteria
Khashim, Zenith , Fitzgerald, Seán , Kadirvel, Ramanathan , Doyle, Karen , Brinjikji, Waleed , Kallmes, David F. , Dai, Daying , Brinjikji, Waleed , Fitzgerald, Seán

Mayo Clinic

Interventional Neuroradiology | April 3, 2019 | Volume: 25 | Issue: 5 | Pages: 502-507

10.1177/1591019918819707 | PMID 30939960 Get It

Background Bacteria and bacterial components have been associated with the activation of coagulation factors and initiating the blood clot formation. The aim of this study was to investigate whether bacterial populations are present in clots retrieved from patients that have suffered a large vessel occlusion acute ischemic stroke (AIS). Materials and methods Clot samples were collected from 20 AIS patients who underwent clot retrieval with mechanical thrombectomy. Patient clinical demographic details were noted. Expression of bacterial 16S rDNA was analyzed by standard and real-time polymerase chain reaction (PCR). Gram staining was performed to identify Gram-positive and Gram-negative bacteria. Results Both the real-time and standard PCR demonstrated no expression of 16S rDNA in any of the 20 clots samples from AIS patients. Gram staining results showed no expression of Gram-positive or Gram-negative bacteria present in the clot samples. Conclusion Our current study found no bacteria populations in the clots of AIS patients.
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia
Manna, Alak , Aulakh, Sonikpreet , Jani, Prachi, Akhtar, Sharoon , Coignet, Marie V. , Meghji, Zahara, Bhatia, Kirtipal , Sharma, Aarushi , Sher, Taimur , Alegria, Victoria R., Chini, Eduardo N. , Chanan‐Khan, Asher , Paulus, Aneel , Ahmed, Salman , Alegria, Victoria, Malavasi, Fabio , Chanan-Khan, Asher, Paulus, Aneel , Ahmed, Salman , Heckman, Michael G. , Malavasi, Fabio , Ailawadhi, Sikander

Mayo Clinic

Clinical Cancer Research | April 2, 2019 | Volume: 25 | Issue: 13 | Pages: 3974-3985

10.1158/1078-0432.ccr-18-3412 | PMID 30940652 Get It

AbstractPurpose:CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 mAb). The clinical importance of CD38 in patients with chronic lymphocytic leukemia (CLL) has been known for over 2 decades, although it's relevance as a therapeutic target in CLL remains understudied.Experimental Design:We investigated the biological effects and antitumor mechanisms engaged by daratumumab in primary CLL cells. Besides its known immune-effector mechanisms (antibody-dependent cell-mediated cytotoxicity, complement-dependent death, and antibody-dependent cellular phagocytosis), we also measured direct apoptotic effects of daratumumab alone or in combination with ibrutinib. In vivo antileukemic activity was assessed in a partially humanized xenograft model. The influence of CD38 on B-cell receptor (BCR) signaling was measured via immunoblotting of Lyn, Syk, BTK, PLCγ2, ERK1/2, and AKT.Results:In addition to immune-effector mechanisms; daratumumab also induced direct apoptosis of primary CLL cells, which was partially dependent on FcγR cross-linking. For the first time, we demonstrated the influence of CD38 on BCR signaling where interference of CD38 downregulated Syk, BTK, PLCγ2, ERK1/2, and AKT; effects that were further enhanced by addition of ibrutinib. In comparison to single-agent treatment, the combination of ibrutinib and daratumumab resulted in significantly enhanced anti-CLL activity in vitro and significantly decreased tumor growth and prolonged survival in the in vivo CLL xenograft model.Conclusions:Overall, our data demonstrate the antitumor mechanisms of daratumumab in CLL; furthermore, we show how cotargeting BTK and CD38 lead to a robust anti-CLL effect, which has clinical implications.
American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems
Hall, S. , Neel, Gregory S., Howard, Brittany E. , Nagel, Thomas H. , Hayden, Richard E. , Hinni, Michael L., Hall, Scott R , Chang, Brent A. , Lott, David G. , Zhang, Nan

Mayo Clinic

Head & Neck | April 2, 2019 | Volume: 41 | Issue: 8 | Pages: 2716-2723

10.1002/hed.25749 | PMID 30939209 Get It

AbstractBackgroundThe American Joint Committee on Cancer (AJCC) eighth edition introduces a staging system specific for human papilloma virus positive oropharyngeal cancer with separate clinical (AJCC 8c) and pathological (AJCC 8p) criteria.MethodsIn this retrospective cohort study, preoperative imaging and pathology reports were used to stage patients based on the AJCC 8c and AJCC 8p criteria, respectively. The primary endpoint was agreement between AJCC 8c and AJCC 8p.ResultsA total of 213 patients met inclusion criteria. Kappa statistics showed poor agreement (κ = 0.3275) between AJCC 8c and AJCC 8p. In total, 30.3% of patient's preoperative AJCC 8c stage changed based on the postoperative pathologic staging (AJCC 8p) with 73.4% of those being upstaged.ConclusionThese data suggest that disagreement exists between AJCC 8c and AJCC 8p, in part due to the separate clinical and pathological staging criteria. This discrepancy should be considered as the new system is implemented.
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Evgin, Laura , Kottke, Timothy, Thompson, Jill , Molan, Amy M. , Driscoll, Christopher B. , Schuelke, Matthew , Shim, Kevin G. , Wongthida, Phonphimon , Ilett, Elizabeth J. , Smith, Karen Kaluza, Pulido, José S. , Pandha, Hardev , Selby, Peter J. , Harrington, Kevin J. , Melcher, Alan , Vile, Richard G. , Huff, Amanda L. , Shim, Kevin G , Ilett, Elizabeth J , Melcher, Alan A , Harrington, Kevin , Driscoll, Christopher , Harris, Reuben S. , Coffey, Matt C.

Mayo Clinic

Cancer Immunology Research | April 2, 2019 | Volume: 7 | Issue: 5 | Pages: 828-840

10.1158/2326-6066.cir-18-0013 | PMID 30940643 Get It

Abstract Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). We show here that T cells that recognize tumor-associated antigens can directly kill tumor cells if used at high effector-to-target ratios. However, when these tumor-reactive T cells were present at suboptimal ratios, direct T-cell–mediated tumor cell killing was reduced and the ability of tumor cells to evolve away from a coapplied therapy (oncolytic or suicide gene therapy) was promoted. This T-cell–mediated increase in therapeutic resistance was associated with C to T transition mutations that are characteristic of APOBEC3 cytosine deaminase activity and was induced through a TNFα and protein kinase C–dependent pathway. Short hairpin RNA inhibition of endogenous APOBEC3 reduced rates of tumor escape from oncolytic virus or suicide gene therapy to those seen in the absence of antitumor T-cell coculture. Conversely, overexpression of human APOBEC3B in tumor cells enhanced escape from suicide gene therapy and oncolytic virus therapy both in vitro and in vivo. Our data suggest that weak affinity or low frequency T-cell responses against tumor antigens may contribute to the ability of tumor cells to evolve away from first-line therapies. We conclude that immunotherapies need to be optimized as early as possible so that, if they do not kill the tumor completely, they do not promote treatment resistance.
Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment
Jack, Clifford R. , Petersen, Ronald C. , Jack, Clifford R

Mayo Clinic

JAMA | April 2, 2019 | Volume: 321 | Issue: 13 | Pages: 1258

10.1001/jama.2019.1998 | PMID 30938781 Get It

Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma
Şahin, İlyas , Kawano, Yawara , Sklavenitis‐Pistofidis, Romanos , Mishima, Yuji , Manier, Salomon , Sacco, Antonio , Carrasco, Ruben D. , Roccaro, Aldo M. , Ghobrial, Irene M. , Roccaro, Aldo M , Witzig, T.E. , Ghobrial, Irene M , Sklavenitis-Pistofidis, Romanos , Moschetta, Michele , Fonseca, Rafaël , Witzig, Thomas E.

Mayo Clinic

Blood Advances | April 2, 2019 | Volume: 3 | Issue: 7 | Pages: 995-1002

10.1182/bloodadvances.2018028456 | PMID 30940634 Get It

Abstract Citron Rho-interacting serine/threonine kinase (CIT) is a serine/threonine kinase that acts as a key component of the midbody and is essential for cytokinesis. CIT has been reported to be highly expressed in some tumor tissues and to play a role in cancer proliferation; however, the significance of CIT has not been investigated in multiple myeloma (MM). Here, we identified, by protein microarray and immunohistochemistry, that CIT is 1 of the upregulated proteins in the plasma cells of MM patients compared with healthy controls. Analysis of a gene expression profile data set showed that MM patients with high CIT gene expression had significantly worse overall survival compared with MM patients with low CIT gene expression. CIT silencing in MM cell lines induced cytokinesis failure and resulted in decreased MM cell proliferation in vitro and in vivo. TP53 expression was found to be an independent predictor of CIT dependency, with low-TP53 cell lines exhibiting a strong dependency on CIT. This study provides the rationale for CIT being a potential therapeutic target in MM in future trials.
The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?
Miller, Virginia M. , Naftolin, Frederick , Asthana, Sanjay , Black, Dennis M. , Budoff, Matthew J. , Cedars, Marcelle I. , Dowling, N. Maritza , Gleason, Carey E. , Hodis, Howard N., Jayachandran, Muthuvel , Kantarci, Kejal , Løbo, Rogerio A. , Pal, Lubna , Taylor, Hugh S. , Harman, S. Mitchell , Asthana, Sanjay , Kantarci, Kejal , Budoff, Matthew , Brinton, Eliot A. , Manson, JoAnn E. , Santoro, Nanette F.

Mayo Clinic

Menopause | April 2, 2019 | Volume: 26 | Issue: 9 | Pages: 1071-1084

10.1097/gme.0000000000001326 | PMID 31453973 Get It

Abstract Objective: The Kronos Early Estrogen Prevention Study (KEEPS) was designed to address gaps in understanding the effects of timely menopausal hormone treatments (HT) on cardiovascular health and other effects of menopause after the premature termination of the Women's Health Initiative. Method: The KEEPS was a randomized, double-blinded, placebo-controlled trial to test the hypothesis that initiation of HT (oral conjugated equine estrogens [o-CEE] or transdermal 17β-estradiol [t-E 2 ]) in healthy, recently postmenopausal women ( n = 727) would slow the progression of atherosclerosis as measured by changes in carotid artery intima-media thickness (CIMT). Results: After 4 years, neither HT affected the rate of increase in CIMT. There was a trend for reduced accumulation of coronary artery calcium with o-CEE. There were no severe adverse effects, including venous thrombosis. Several ancillary studies demonstrated a positive effect on mood with o-CEE, and reduced hot flashes, improved sleep, and maintenance of bone mineral density with both treatments. Sexual function improved with t-E 2 . There were no significant effects of either treatment on cognition, breast pain, or skin wrinkling. Variants of genes associated with estrogen metabolism influenced the age of menopause and variability in effects of the HT on CIMT. Platelet activation associated with the development of white matter hyperintensities in the brain. Conclusions: KEEPS and its ancillary studies have supported the value and safety of the use of HT in recently postmenopausal women and provide a perspective for future research to optimize HT and health of postmenopausal women. The KEEPS continuation study continues to pursue these issues.